David Beversdorf, MD
Behavioral Neurology & Neuropsychiatry · Columbia, MONPI 1639253982
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $2,825 of the $2,997 with a category attached, or 94.3%. Biogen accounts for 94.6% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2020 at $2,835 and has fallen 99.3% since, to $20 in 2025.
Across 5 payments — averaging $599.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$3K
- SK Life Science, Inc.$86
- Sanofi$57
- Novo Nordisk$20
Across 7 payments — averaging $25,231 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Otsuka Pharmaceutical Development & Commercialization, Inc.$176K
- Siemens Medical Solutions USA, Inc.$139
What the payments were for
- Speaking & faculty fees$2,82594%
- Food & beverage$1635%
- Education$100%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biogen | 2 | $2,835 |
| SK Life Science, Inc. | 1 | $86 |
| Sanofi | 1 | $57 |
| Novo Nordisk | 1 | $20 |
How this compares
Too few behavioral neurology & neuropsychiatry providers in Missourito place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Memantine Hcl ErMemantine Hcl | 51 | $2,886 |
| Memantine Hcl | 117 | $2,622 |
| Propranolol Hcl | 65 | $2,369 |
| Methylphenidate ErMethylphenidate Hcl | 11 | $2,118 |
| Quetiapine Fumarate | 39 | $1,524 |
| Aripiprazole | 16 | $1,380 |
| Divalproex Sodium ErDivalproex Sodium | 13 | $1,335 |
| Donepezil Hcl | 95 | $1,218 |
| Galantamine Hbr | 14 | $893 |
| Propranolol Hcl ErPropranolol Hcl | 16 | $885 |
| Levetiracetam | 26 | $879 |
| Buspirone Hcl | 13 | $630 |
| Atomoxetine Hcl | 13 | $622 |
| Pramipexole DihydrochloridePramipexole Di-Hcl | 13 | $503 |
| Haloperidol | 20 | $461 |
Paid to pharmacies, not to this prescriber.
Other behavioral neurology & neuropsychiatry in Columbia
- Joel ShenkerColumbia$32
- Sharmila Suri MohanramJefferson City$10K
- Subha SubramanianSaint Louis$395
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.